Physicians′ Desk Reference: Hospital Library 2006
Autor Physicians′ Desk Reference (PDR)en Limba Engleză Hardback – 11 dec 2005
Preț: 572.87 lei
Preț vechi: 603.02 lei
-5% Nou
Puncte Express: 859
Preț estimativ în valută:
109.67€ • 112.79$ • 90.98£
109.67€ • 112.79$ • 90.98£
Comandă specială
Livrare economică 28 ianuarie-11 februarie
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781563635267
ISBN-10: 1563635267
Pagini: 3000
Dimensiuni: 200 x 250 x 15 mm
Greutate: 0.67 kg
Ediția:60th Edition
Colecția Thomson PDR
Locul publicării:Chichester, United Kingdom
ISBN-10: 1563635267
Pagini: 3000
Dimensiuni: 200 x 250 x 15 mm
Greutate: 0.67 kg
Ediția:60th Edition
Colecția Thomson PDR
Locul publicării:Chichester, United Kingdom
Descriere
The authoritative source of FDA–approved information on prescription drugs.
Physicians have turned to PDR® for the latest word on prescription drugs for 60 years! Today, PDR® is considered the standard prescription drug reference and can be found in virtually every physician s office, hospital, and pharmacy in the U.S. In fact, nine out of ten doctors consider PDR their most important drug reference source. The 60th edition is over 3,000 pages our most comprehensive edition ever! New format allows dramatically improved readability and easier access to the information. Among the new drugs featured are:
Boniva (ibandronate sodium), the first once–monthly oral tablet for the treatment of postmenopausal osteoporosis
Combunox (oxycodone HCl and ibuprofen), a new opioid/nonsteroidal anti–inflammatory combination product indicated for the short–term management of acute, moderate–to–severe pain
Equetro (carbamazepine),the first extended–release carbamazepine approved for treatment of bipolar disorder
Fosrenol (lanthanum carbonate), a new phosphate binder that reduces elevated blood levels of phosphate in patients with end–stage renal disease
Tarceva (erlotinib), a new HER1/EGFR tyrosine kinase inhibitor for the treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy regimen
Vantas (histrelin acetate), a new long–acting implant for the palliative treatment of advanced prostate cancer
Ventavis (iloprost), a new inhalation solution for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
You ll find the most complete data on more than 4,000 drugs by brand and generic name (both in the same convenient index), manufacturer and product category. Your 2006 PDR provides usage information and warnings, drug interactions, plus more than 2,000 full–size, full–color photos cross–referenced to the drug. You will also find:
Phonetic spelling A key to controlled substances Dosages Clinical pharmacology FDA use–in–pregnancy ratings Adverse reactions Contraindications Pediatric use And all other FDA–required information
Physicians have turned to PDR® for the latest word on prescription drugs for 60 years! Today, PDR® is considered the standard prescription drug reference and can be found in virtually every physician s office, hospital, and pharmacy in the U.S. In fact, nine out of ten doctors consider PDR their most important drug reference source. The 60th edition is over 3,000 pages our most comprehensive edition ever! New format allows dramatically improved readability and easier access to the information. Among the new drugs featured are:
Boniva (ibandronate sodium), the first once–monthly oral tablet for the treatment of postmenopausal osteoporosis
Combunox (oxycodone HCl and ibuprofen), a new opioid/nonsteroidal anti–inflammatory combination product indicated for the short–term management of acute, moderate–to–severe pain
Equetro (carbamazepine),the first extended–release carbamazepine approved for treatment of bipolar disorder
Fosrenol (lanthanum carbonate), a new phosphate binder that reduces elevated blood levels of phosphate in patients with end–stage renal disease
Tarceva (erlotinib), a new HER1/EGFR tyrosine kinase inhibitor for the treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy regimen
Vantas (histrelin acetate), a new long–acting implant for the palliative treatment of advanced prostate cancer
Ventavis (iloprost), a new inhalation solution for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
You ll find the most complete data on more than 4,000 drugs by brand and generic name (both in the same convenient index), manufacturer and product category. Your 2006 PDR provides usage information and warnings, drug interactions, plus more than 2,000 full–size, full–color photos cross–referenced to the drug. You will also find:
Phonetic spelling A key to controlled substances Dosages Clinical pharmacology FDA use–in–pregnancy ratings Adverse reactions Contraindications Pediatric use And all other FDA–required information
Textul de pe ultima copertă
The authoritative source of FDA–approved information on prescription drugs.
Physicians have turned to PDR® for the latest word on prescription drugs for 60 years! Today, PDR® is considered the standard prescription drug reference and can be found in virtually every physician s office, hospital, and pharmacy in the U.S. In fact, nine out of ten doctors consider PDR their most important drug reference source. The 60th edition is over 3,000 pages our most comprehensive edition ever! New format allows dramatically improved readability and easier access to the information. Among the new drugs featured are:
Boniva (ibandronate sodium), the first once–monthly oral tablet for the treatment of postmenopausal osteoporosis
Combunox (oxycodone HCl and ibuprofen), a new opioid/nonsteroidal anti–inflammatory combination product indicated for the short–term management of acute, moderate–to–severe pain
Equetro (carbamazepine),the first extended–release carbamazepine approved for treatment of bipolar disorder
Fosrenol (lanthanum carbonate), a new phosphate binder that reduces elevated blood levels of phosphate in patients with end–stage renal disease
Tarceva (erlotinib), a new HER1/EGFR tyrosine kinase inhibitor for the treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy regimen
Vantas (histrelin acetate), a new long–acting implant for the palliative treatment of advanced prostate cancer
Ventavis (iloprost), a new inhalation solution for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
You ll find the most complete data on more than 4,000 drugs by brand and generic name (both in the same convenient index), manufacturer and product category. Your 2006 PDR provides usage information and warnings, drug interactions, plus more than 2,000 full–size, full–color photos cross–referenced to the drug. You will also find:
Phonetic spelling A key to controlled substances Dosages Clinical pharmacology FDA use–in–pregnancy ratings Adverse reactions Contraindications Pediatric use And all other FDA–required information
Physicians have turned to PDR® for the latest word on prescription drugs for 60 years! Today, PDR® is considered the standard prescription drug reference and can be found in virtually every physician s office, hospital, and pharmacy in the U.S. In fact, nine out of ten doctors consider PDR their most important drug reference source. The 60th edition is over 3,000 pages our most comprehensive edition ever! New format allows dramatically improved readability and easier access to the information. Among the new drugs featured are:
Boniva (ibandronate sodium), the first once–monthly oral tablet for the treatment of postmenopausal osteoporosis
Combunox (oxycodone HCl and ibuprofen), a new opioid/nonsteroidal anti–inflammatory combination product indicated for the short–term management of acute, moderate–to–severe pain
Equetro (carbamazepine),the first extended–release carbamazepine approved for treatment of bipolar disorder
Fosrenol (lanthanum carbonate), a new phosphate binder that reduces elevated blood levels of phosphate in patients with end–stage renal disease
Tarceva (erlotinib), a new HER1/EGFR tyrosine kinase inhibitor for the treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy regimen
Vantas (histrelin acetate), a new long–acting implant for the palliative treatment of advanced prostate cancer
Ventavis (iloprost), a new inhalation solution for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
You ll find the most complete data on more than 4,000 drugs by brand and generic name (both in the same convenient index), manufacturer and product category. Your 2006 PDR provides usage information and warnings, drug interactions, plus more than 2,000 full–size, full–color photos cross–referenced to the drug. You will also find:
Phonetic spelling A key to controlled substances Dosages Clinical pharmacology FDA use–in–pregnancy ratings Adverse reactions Contraindications Pediatric use And all other FDA–required information